Quick links

Secure login

Secure file transfer protocol

Register or renew user

Contact us

Trouble logging in? Forgot password? We can help!

philavax@phila.gov

215-685-6784

215-238-6944

Register a clinic

Fill out both forms, then either email or fax them to us at the contact above.

Clinic registration form
Provider agreement form

On behalf of patients

Request or update record
Patient update request

Looking for something else?

PhilaVax program info
Flat file reporting guide
More PhilaVax resources

Moderna Monovalent Products Set to Expire

28 Feb Moderna Monovalent Products Set to Expire

Posted at 15:09h in COVID-19 by

Moderna Monovalent Products Set to Expire

PDPH has some important updates to share regarding Moderna COVID-19 vaccines. Moderna-10 and Moderna-5 monovalent products for individuals aged 6 and older are set to expire in early April. There will not be any additional shelf-life extensions for these products.

The Moderna 6-11 and 12+ monovalent products ordered in the next few weeks will be short-dated, with expirations in early April.

Providers will need to order monovalent vaccines produced by Pfizer (ages 6 and older) and Novavax (ages 12 and older) to begin and complete primary series for their patient populations.

PDPH will accept orders for Moderna monovalent vaccines through March 8 to support primary series vaccinations. After March 8, providers will need to order alternative vaccines from Pfizer (ages 6 and older) and Novavax (aged 12 and older) for individuals seeking monovalent, primary series vaccines.

In anticipation of the upcoming expiration of Moderna’s monovalent vaccines for people ages 6 and older, providers should be aware that depending on the date of the first Moderna dose, the same product may not be available to complete the primary series. In this case, a different COVID-19 vaccine may be administered to complete the primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose.

Please read CDC guidance on interchanging COVID-19 vaccines here.

The U.S. government has an ample supply of monovalent vaccines produced by Pfizer (ages 6 and older) and Novavax (ages 12 and older) to begin and complete their primary series.

In summary:

  • All Moderna adult (12+) and pediatric (6-11) monovalent COVID-19 vaccines will reach their expiry in early April.
  • Moderna is not seeking a shelf-life extension for these vaccines.
  • Ordering for Moderna adult (12+) and pediatric (6-11) monovalent COVID-19 vaccines will end on March 8.
  • Ordering for Moderna bivalent vaccines for all age groups will remain available.
  • Pfizer (12+ and 5-11) and Novavax (12+) monovalent vaccines remain available for ordering for primary series vaccination. There is ample supply of both products, and providers can order additional supply.